Form 4: Fulgent Genetics CEO Ming Hsieh Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Fulgent Genetics CEO Ming Hsieh sold 2,227 shares of common stock to cover tax obligations arising from the vesting of restricted stock units.
Summary
- Fulgent Genetics CEO Ming Hsieh sold 2,227 shares of common stock on November 25, 2024, at a weighted average price of $18.2593.
- The sale was to satisfy tax withholding obligations related to the vesting of restricted stock units granted on February 23, 2023.
- The shares were sold in multiple transactions with prices ranging from $18.12 to $18.50.
- Following the transaction, Mr. Hsieh directly owns 703,711 shares and indirectly owns 7,895,115 shares through The Ming Hsieh Trust, 220,816 shares through the Dynasty Trust, and 2,000 shares through Uniform Transfers to Minor Act accounts.
- Mr. Hsieh disclaims beneficial interest in the shares held by the Dynasty Trust except for any pecuniary interest.
Sentiment
Score: 5
Explanation: The document reflects a routine transaction related to executive compensation and does not indicate any significant positive or negative sentiment.
Industry Context
This is a routine transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax obligations when restricted stock units vest.
Comparison to Industry Standards
- Executive stock sales to cover tax obligations are a common practice across publicly traded companies.
- The sale of 2,227 shares is relatively small compared to the total holdings of Mr. Hsieh, which include 703,711 directly held shares and over 8 million indirectly held shares.
- Similar transactions are regularly reported by executives at comparable companies in the biotechnology and healthcare sectors.
Stakeholder Impact
- The sale of shares by the CEO may have a minor impact on the stock price, but it is unlikely to be significant given the relatively small number of shares sold compared to the total outstanding shares.
- The transaction does not have a direct impact on employees, customers, or suppliers.
Key Dates
| Date | Description |
|---|---|
| 02/23/2023 | Date of grant of restricted stock units that led to the tax obligations. |
| 02/27/2023 | Date the original grant of restricted stock units was reported on Form 4. |
| 11/25/2024 | Date of the stock sale transaction. |
| 11/27/2024 | Date the Form 4 was signed. |
Keywords
Fulgent Genetics, Ming Hsieh, stock sale, insider trading, Form 4, tax obligations, restricted stock units
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.